Last mentioned: Mar 6, 2026
Regulatory Approval
Japan's Ministry of Health officially approves the therapy for clinical use.
Data Submission
Sumitomo Pharma submits trial data to Japan's PMDA for regulatory review.
Clinical Trial Launch
Kyoto University begins the first human clinical trial for iPS-derived Parkinson's treatment.
Nobel Prize Awarded
Shinya Yamanaka wins the Nobel Prize for the discovery of iPS cells.
Japan's Ministry of Health has granted regulatory approval for a groundbreaking stem-cell treatment for Parkinson's disease, marking the first time induced pluripotent stem cells (iPS) have been cleared for clinical use. The therapy, developed by Kyoto University and Sumitomo Pharma, aims to restore dopamine-producing neurons in the brain.
This page surfaces every story mentioning Shinya Yamanaka across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Shinya Yamanaka was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |